Corline Biomedical Information

Corline was founded in 1991 by three former employees of the Swedish pharmaceutical and biotechnology company Pharmacia with the goal to commercialize an extra corporeal blood pump. The blood pump used a unique and proprietary coating technology that later became the basis of the Corline's offering to the medical device industry - the Corline Heparin Surface, CHS™. During 1997-2005 Corline delivered more than 100,000 coronary stents coated with CHS™. As result of a research partnership with Uppsala University a new line of business was added in 2005, where heparin based compounds were used to treat biological products for applications within regenerative medicine. Through this partnership Corline further developed its technology base to allow heparin to be immobilized onto living cells and the surface of tissues without compromising viability, and ultimately improving transplant outcome through enhanced biocompatibility. Due to its exclusive value proposition, Corline is set to be a leader in the surface modification sector.